The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Patients with cancer want information and advice early in the disease course about how to deal with the financial stressors ...

The pembrolizumab group did experience more grade 3 or higher ... Funding for the study was provided by Merck Sharp & Dohme. Van Gorp reported various relationships with AbbVie, AstraZeneca, Amgen, ...